Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Sarepta Therapeutics, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sarepta Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Sarepta Therapeutics, Inc. - The report provides overview of Sarepta Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Sarepta Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Sarepta Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Sarepta Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sarepta Therapeutics, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sarepta Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Sarepta Therapeutics, Inc. Snapshot 7 Sarepta Therapeutics, Inc. Overview 7 Key Information 7 Key Facts 7 Sarepta Therapeutics, Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Sarepta Therapeutics, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Sarepta Therapeutics, Inc. - Pipeline Products Glance 13 Sarepta Therapeutics, Inc. - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Sarepta Therapeutics, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Sarepta Therapeutics, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Sarepta Therapeutics, Inc. - Drug Profiles 18 eteplirsen 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 SRP-4053 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 SRP-4045 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 AVI-7288 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 radavirsen 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 PMO-25 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 SRP-4008 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 SRP-4044 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 SRP-4050 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 SRP-4052 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 SRP-4055 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Antisense Oligonucleotide for Acinetobacter baumannii Infections 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Antisense Oligonucleotide for Methicillin Resistant Staphylococcus Aureus Infections 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Antisense Oligonucleotide to Activate Lamin A for Progeria 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Antisense Oligonucleotides for Infectious Diseases 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Bacterial PPMO 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Viral PMO-X 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Sarepta Therapeutics, Inc. - Pipeline Analysis 49 Sarepta Therapeutics, Inc. - Pipeline Products by Target 49 Sarepta Therapeutics, Inc. - Pipeline Products by Route of Administration 50 Sarepta Therapeutics, Inc. - Pipeline Products by Molecule Type 51 Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action 52 Sarepta Therapeutics, Inc. - Recent Pipeline Updates 53 Sarepta Therapeutics, Inc. - Dormant Projects 66 Sarepta Therapeutics, Inc. - Discontinued Pipeline Products 67 Discontinued Pipeline Product Profiles 67 AVI-4065 67 AVI-6002 67 AVI-7537 67 Sarepta Therapeutics, Inc. - Company Statement 68 Sarepta Therapeutics, Inc. - Locations And Subsidiaries 71 Head Office 71 Other Locations & Subsidiaries 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Sarepta Therapeutics, Inc., Key Information 7 Sarepta Therapeutics, Inc., Key Facts 7 Sarepta Therapeutics, Inc. - Pipeline by Indication, 2016 9 Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016 11 Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 12 Sarepta Therapeutics, Inc. - Pre-Registration, 2016 13 Sarepta Therapeutics, Inc. - Phase II, 2016 14 Sarepta Therapeutics, Inc. - Phase I, 2016 15 Sarepta Therapeutics, Inc. - Preclinical, 2016 16 Sarepta Therapeutics, Inc. - Discovery, 2016 17 Sarepta Therapeutics, Inc. - Pipeline by Target, 2016 49 Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016 50 Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016 51 Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 52 Sarepta Therapeutics, Inc. - Recent Pipeline Updates, 2016 53 Sarepta Therapeutics, Inc. - Dormant Developmental Projects,2016 66 Sarepta Therapeutics, Inc. - Discontinued Pipeline Products, 2016 67 Sarepta Therapeutics, Inc., Other Locations 71 Sarepta Therapeutics, Inc., Subsidiaries 71
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.